AAML1531 Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Brief description of study

If you are the parent or guardian of a child diagnosed with acute myeloid leukemia (AML) also born with Down Syndrome (DS), your child may qualify to participate in a clinical trial investigating "response based" risk stratification for treatment of this disease.  Patients whose leukemia responds well to treatment, he/she will receive less treatment than children with DS-AML receive to date, in an effort to maintain high cure rates while decreasing the number or severity of side-effects.  For patients, in whom leukemia does not respond well to the first course of treatment, then they will be called "high risk" and treatment will be changed to receive higher doses of cytarabine (Ara-C) and the addition of mitoxantrone.  This is a change from the standard of care.  This clinical trial is designed to find the best balance between killing the cancer and lowering the risk of future side effects in this group of patients.

 


Clinical Study Identifier: s16-01673
ClinicalTrials.gov Identifier: NCT02521493
Principal Investigator: Sharon L Gardner.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.